Details of the Drug Combination

General Information of Drug Combination (ID: DCD3GLE)

Drug Combination Name

Picoplatin DFN-15

Indication

Disease Entry	Status	REF
Colon carcinoma	Investigative	[1]

Component Drugs

Picoplatin DM0PIY6

DFN-15 DM3BF9B

Small molecular drug

N.A.

High-throughput Screening Result

Testing Cell Line: KM12

Zero Interaction Potency (ZIP) Score: 1.12

Bliss Independence Score: 3.47

Loewe Additivity Score: 12.16

LHighest Single Agent (HSA) Score: 11.76

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Large cell lung carcinoma	DCTGZ41	NCI-H460	Investigative	[4]
------------------------------------------------------------------------------------

References

1	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.